Cyclo Therapeutics, Inc.
CYTH
$0.7206
$0.00991.39%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -52.82% | 5.12% | 32.87% | 66.70% | 9.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -52.82% | 5.12% | 32.87% | 66.70% | 9.58% |
| Cost of Revenue | -48.74% | -21.11% | 24.56% | 22.89% | 12.50% |
| Gross Profit | -53.17% | 12.99% | 33.55% | 70.98% | 9.33% |
| SG&A Expenses | 71.94% | 44.92% | 40.39% | -9.12% | -3.04% |
| Depreciation & Amortization | -54.17% | -54.17% | -54.17% | -2.04% | -5.88% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.95% | 21.24% | 2.95% | 15.17% | 11.96% |
| Operating Income | -73.87% | -21.65% | -2.04% | -13.24% | -12.22% |
| Income Before Tax | -85.12% | -29.00% | 13.26% | -13.29% | -12.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -85.12% | -29.00% | 13.26% | -13.29% | -12.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -85.12% | -29.00% | 13.26% | -13.29% | -12.35% |
| EBIT | -73.87% | -21.65% | -2.04% | -13.24% | -12.22% |
| EBITDA | -74.01% | -21.72% | -2.10% | -13.25% | -12.24% |
| EPS Basic | -4.34% | 36.74% | 66.62% | 56.63% | 41.38% |
| Normalized Basic EPS | 12.93% | 46.31% | 66.70% | 56.64% | 41.44% |
| EPS Diluted | -4.34% | 36.40% | 66.62% | 56.63% | 41.38% |
| Normalized Diluted EPS | 12.93% | 46.31% | 66.70% | 56.64% | 41.44% |
| Average Basic Shares Outstanding | 77.43% | 103.95% | 159.78% | 161.25% | 91.67% |
| Average Diluted Shares Outstanding | 77.43% | 103.95% | 159.78% | 161.25% | 91.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
